VFA
CLDX icon

Values First Advisors’s Celldex Therapeutics CLDX Stock Holding History

Values First Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,728
Closed -$210K – 183
2025
Q4 		$210K Buy
+7,728
New +$204K 0.11% 163
2025
Q2 		– Sell
-29,933
Closed -$550K – 186
2025
Q1 		$550K Buy
29,933
+924
+3% +$20.6K 0.32% 83
2024
Q4 		$733K Buy
29,009
+4,837
+20% +$131K 0.4% 70
2024
Q3 		$822K Buy
24,172
+2,853
+13% +$109K 0.45% 63
2024
Q2 		$789K Buy
21,319
+1,627
+8% +$61.4K 0.47% 60
2024
Q1 		$826K Buy
19,692
+12,293
+166% +$505K 0.48% 60
2023
Q4 		$293K Buy
+7,399
New +$218K 0.18% 130
2023
Q3 		– Sell
-7,560
Closed -$257K – 166
2023
Q2 		$257K Buy
7,560
+2,258
+43% +$76.1K 0.15% 139
2023
Q1 		$191K Sell
5,302
-2,238
-30% -$96.6K 0.12% 142
2022
Q4 		$336K Buy
+7,540
New +$269K 0.23% 111

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Values First Advisors's CLDX Position: Q1 2026 in Review

Values First Advisors sold out of Celldex Therapeutics (CLDX) in Q1 2026, closing a stake of 7,728 shares — an estimated $210K sold.

Values First Advisors first reported a position in CLDX in Q4 2022 and held it in 10 quarters. The position peaked at $826K in Q1 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Values First Advisors reported no remaining Celldex Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Values First Advisors sold 7,728 Celldex Therapeutics shares in Q1 2026, an estimated $210K.
  • Values First Advisors first reported a position in Celldex Therapeutics in Q4 2022 and held it in 10 quarters.
  • Values First Advisors's Celldex Therapeutics position peaked at $826K in Q1 2024.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Values First Advisors's 13F filing for Q1 2026, filed 17 Apr 2026.